CYTOKINETICS INC
CYTKAPI behind this page
CYTK Q1 2026 request
Playground key active
/api/financials?ticker=CYTK&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 19,355 | 1,579 | +1125.8% |
Show Product Lines breakouts |
|||
| Collaboration Revenues [Member] | 2,637 | 1,579 | +67.0% |
| Collaboration Revenues [Member] · Bayer License Agreement [Member] | 2.1 | 1.4 | +50.0% |
| Collaboration Revenues [Member] · CN | 0.5 | 0.1 | +400.0% |
| License and Milestone Revenues [Member] | 11,929 | — | — |
| License and Milestone Revenues [Member] · Bayer License Agreement [Member] | 11.9 | — | — |
| Net Product Revenue [Member] | 4,789 | — | — |
| Research & Development | 95,525 | 98,262 | -2.8% |
Show Type Of Arrangement breakouts |
|||
| Research Collaboration [Member] | 1.2 | — | — |
| Selling, General & Administrative | 104,896 | 57,369 | +82.8% |
| Cost Of Goods Sold | 160 | — | — |
| Collaboration Cost Of Sales | 2,392 | 1,579 | +51.5% |
| Operating Expenses | 202,973 | 157,210 | +29.1% |
| Operating Income | -183,618 | -155,631 | -18.0% |
| Interest Expense Other | -14,519 | -8,868 | -63.7% |
| Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements | -18,816 | -14,078 | -33.7% |
| Non-Operating Income (Expense) | 11,022 | 13,701 | -19.6% |
| Derivative Gain Loss On Derivative Net | 1,500 | -400 | +475.0% |
Show Debt Instrument breakouts |
|||
| RP Multi Tranche Loan [Member] | -1,500 | 400 | -475.0% |
| Liabilities Fair Value Adjustment | -1,600 | 3,900 | -141.0% |
| Net Income | -206,031 | -161,376 | -27.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | -206,031 | -161,376 | -27.7% |
| EPS (Basic) | -1.67 | -1.36 | -22.8% |
| EPS (Diluted) | -1.67 | -1.36 | -22.8% |
| Wtd Avg Shares (Basic) | 123,273 | 118,496 | +4.0% |
| Wtd Avg Shares (Diluted) | 123,273 | 118,496 | +4.0% |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -1,838 | -541 | -239.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,838 | -541 | -239.7% |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -404 | -312 | -29.5% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -404 | -312 | -29.5% |
| Comprehensive Income | -208,273 | -162,229 | -28.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 129,843 | 73,680 | +76.2% |
| Available For Sale Securities Debt Securities Current | 688,707 | 864,538 | -20.3% |
| Accounts Receivable | 6,827 | — | — |
Show Type Of Arrangement breakouts |
|||
| Bayer License Agreement [Member] | 2.1 | — | — |
| Sanofi License Agreement [Member] | 0.2 | — | — |
| Inventory | 154 | — | — |
| Prepaid Expenses & Other Current Assets | 13,934 | 15,823 | -11.9% |
| Total Current Assets | 839,465 | 956,053 | -12.2% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 254,719 | — | — |
| Property, Plant & Equipment | 82,438 | 67,175 | +22.7% |
| Operating Lease Right-of-Use Assets | 74,545 | — | — |
| Inventory Noncurrent | 3,843 | — | — |
| Other Non-Current Assets | 18,468 | 12,697 | +45.5% |
| Total Assets | 1,273,478 | 1,264,051 | +0.7% |
| Current Liabilities | |||
| Accounts Payable | 24,709 | 13,942 | +77.2% |
| Accrued Liabilities | 68,863 | 43,358 | +58.8% |
| Operating Lease Liability Current | 20,960 | 19,574 | +7.1% |
| Current Portion of Long-Term Debt | 44,808 | 12,960 | +245.7% |
| Derivative Liabilities Current | 29,600 | 11,700 | +153.0% |
| Deferred Revenue | 1,653 | — | — |
| Other Liabilities Current | 8,592 | 5,822 | +47.6% |
| Total Current Liabilities | 199,185 | 159,726 | +24.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 247,209 | 92,025 | +168.6% |
| Convertible Notes Noncurrent | 870,511 | — | — |
| Operating Lease Liabilities | 105,235 | 113,353 | -7.2% |
| Total Liabilities | 2,100,046 | 1,530,464 | +37.2% |
| Other Liabilities | |||
| Liabilities Related To Revenue Participation Right Purchase Agreement Net | 539,106 | 476,296 | +13.2% |
| Liabilities Related To R P I Transactions Fairvalue | 138,800 | 133,100 | +4.3% |
| Stockholders' Equity | |||
| Common Stock | 124 | 119 | +4.2% |
| Additional Paid In Capital Common Stock | 2,867,670 | 2,595,063 | +10.5% |
| Accumulated Other Comprehensive Income | -1,612 | 1,545 | -204.3% |
| Retained Earnings | -3,692,750 | -2,863,140 | -29.0% |
| Total Stockholders' Equity | -826,568 | -266,413 | -210.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,612 | 1,545 | -204.3% |
| Additional Paid In Capital | 2,867,670 | 2,595,063 | +10.5% |
| Common Stock | 124 | 119 | +4.2% |
| Retained Earnings | -3,692,750 | -2,863,140 | -29.0% |
| Total Liabilities & Equity | 1,273,478 | 1,264,051 | +0.7% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -206,031 | -161,376 | -27.7% |
| Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement | 18,816 | 14,104 | +33.4% |
| Stock-Based Compensation | 30,394 | 23,549 | +29.1% |
| Non Cash Lease Expense | 1,585 | 1,230 | +28.9% |
| Depreciation & Amortization | 3,378 | 2,300 | +46.9% |
| Realized Investment Gains Losses | -61 | — | — |
| Interest Receivable And Amortization On Investments | -1,874 | -6,174 | +69.6% |
| Paid In Kind Interest | 8,455 | 3,453 | +144.9% |
| Change in Accounts Receivable | 10,937 | 14,638 | -25.3% |
| Change in Prepaid & Other Assets | 2,057 | -376 | +647.1% |
| Change in Inventory | -3,567 | — | — |
| Increase Decrease In Accounts Payable Trade | 1,519 | -4,576 | +133.2% |
| Increase Decrease In Deferred Revenue | 41 | — | — |
| Increase Decrease In Accrued Liabilities | -6,213 | -14,367 | +56.8% |
| Increase Decrease In Operating Lease Liabilities | -1,039 | -2,143 | +51.5% |
| Change in Other Liabilities | -3,954 | 1,621 | -343.9% |
| Net Cash from Operations | -145,457 | -131,617 | -10.5% |
| Investing Activities | |||
| Purchases of Investments | -106,516 | -159,105 | +33.1% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 257,938 | 275,725 | -6.5% |
| Capital Expenditures | -5,930 | -5,664 | -4.7% |
| Net Cash from Investing | 145,492 | 105,956 | +37.3% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 170 | 3,501 | -95.1% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -2,735 | -2,682 | -2.0% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 11,346 | 7,651 | +48.3% |
| Tax Withholding for Share Compensation | -841 | -13 | -6369.2% |
| Net Cash from Financing | 7,770 | 4,754 | +63.4% |
| Amortization of Financing Costs (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Notes [Member] | 204 | 746 | -72.7% |
| 2031 Notes [Member] | 746 | — | — |
| Convertible Notes 2026 [Member] | 27 | 26 | +3.8% |
| Supplemental | |||
| Interest Paid | 1,585 | 9,647 | -83.6% |
| Unpaid Capital Expenditures | 4,186 | 1,494 | +180.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -483 | -270 | -78.9% |
| Net Change in Cash | 7,322 | -21,177 | +134.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 132,954 | 74,055 | +79.5% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.